CryoLife, Inc. (CRY) Announces Quarterly Earnings Results

CryoLife, Inc. (NYSE:CRY) issued its quarterly earnings data on Monday, July 24th. The medical equipment provider reported $0.12 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.10 by $0.02, Bloomberg Earnings reports. The firm had revenue of $47.80 million for the quarter, compared to analyst estimates of $47.02 million. CryoLife had a return on equity of 7.41% and a net margin of 6.16%. The business’s quarterly revenue was up 1.5% compared to the same quarter last year. During the same period last year, the company earned $0.13 EPS. CryoLife updated its FY17 guidance to $40-0.43 EPS.

CryoLife (NYSE CRY) opened at 18.40 on Friday. The stock has a 50 day moving average price of $19.30 and a 200-day moving average price of $17.96. The stock has a market cap of $615.41 million, a PE ratio of 55.76 and a beta of 0.97. CryoLife has a 1-year low of $14.03 and a 1-year high of $20.30.

A number of brokerages have recently weighed in on CRY. BidaskClub lowered CryoLife from a “buy” rating to a “hold” rating in a research report on Monday, July 24th. Zacks Investment Research upgraded CryoLife from a “hold” rating to a “buy” rating and set a $21.00 price objective on the stock in a research report on Thursday, June 8th. Finally, Northland Securities reiterated a “buy” rating and issued a $23.50 price objective on shares of CryoLife in a research report on Friday, April 28th. Two investment analysts have rated the stock with a sell rating and three have given a buy rating to the company. CryoLife has an average rating of “Hold” and a consensus target price of $22.00.

COPYRIGHT VIOLATION WARNING: “CryoLife, Inc. (CRY) Announces Quarterly Earnings Results” was published by Community Financial News and is owned by of Community Financial News. If you are reading this story on another site, it was illegally copied and republished in violation of U.S. & international trademark and copyright legislation. The correct version of this story can be viewed at https://www.com-unik.info/2017/08/12/cryolife-inc-cry-posts-quarterly-earnings-results-beats-expectations-by-0-02-eps-updated-updated.html.

In other CryoLife news, VP Amy Horton sold 9,577 shares of the stock in a transaction on Tuesday, June 27th. The stock was sold at an average price of $20.00, for a total transaction of $191,540.00. Following the sale, the vice president now owns 112,282 shares of the company’s stock, valued at approximately $2,245,640. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 6.00% of the stock is owned by corporate insiders.

Hedge funds have recently made changes to their positions in the stock. Louisiana State Employees Retirement System boosted its stake in shares of CryoLife by 0.9% in the second quarter. Louisiana State Employees Retirement System now owns 11,100 shares of the medical equipment provider’s stock valued at $221,000 after buying an additional 100 shares during the period. Municipal Employees Retirement System of Michigan boosted its stake in shares of CryoLife by 3.2% in the first quarter. Municipal Employees Retirement System of Michigan now owns 6,150 shares of the medical equipment provider’s stock valued at $102,000 after buying an additional 190 shares during the period. Arizona State Retirement System boosted its stake in shares of CryoLife by 1.4% in the first quarter. Arizona State Retirement System now owns 14,054 shares of the medical equipment provider’s stock valued at $234,000 after buying an additional 200 shares during the period. Creative Planning boosted its stake in shares of CryoLife by 3.0% in the second quarter. Creative Planning now owns 6,806 shares of the medical equipment provider’s stock valued at $136,000 after buying an additional 200 shares during the period. Finally, Wells Fargo & Company MN boosted its stake in shares of CryoLife by 0.9% in the second quarter. Wells Fargo & Company MN now owns 31,313 shares of the medical equipment provider’s stock valued at $624,000 after buying an additional 271 shares during the period. 68.13% of the stock is currently owned by institutional investors and hedge funds.

CryoLife Company Profile

CryoLife, Inc (CryoLife) is a medical device manufacturer and processor, and is engaged in the distribution of medical devices and implantable human tissues used in cardiac surgical procedures. The Company operates through two segments: Medical Devices and Preservation Services. The Medical Devices segment includes medical devices, such as BioGlue Surgical Adhesive, BioFoam Surgical Matrix, On-X Life Technologies Holdings, Inc valves and surgical products, CardioGenesis cardiac laser therapy product line, PerClot and PhotoFix.

Earnings History for CryoLife (NYSE:CRY)

What are top analysts saying about CryoLife Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for CryoLife Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit